Genferon Light
GENFERON® LITE 250 thousand IU. – the only combination of interferon alpha-2b and taurine1 in Russia for the treatment of acute respiratory diseases of viral and bacterial etiology in adults and children over 7 years of age, as well as for the treatment of urogenital tract infections in women, incl. at 13-40 weeks of pregnancy2
Features of the composition and properties of the components of suppositories GENFERON® LITE 250 thousand IU:
- a unique combination drug1, the complex therapeutic effect of which is determined by the components included in its composition: recombinant interferon alpha-2b has a universal3 direct antiviral, immunomodulatory, antiproliferative and indirect antibacterial effect2;
- taurine is a strong antioxidant, helps normalize metabolic processes and tissue regeneration, has anti-inflammatory4, membrane-stabilizing and immunomodulatory effects; also helps maintain the biological activity of interferon, enhancing the therapeutic effect of the drug2;
Features of the release form - suppositories GENFERON® LIGHT 250 thousand IU:
- suppositories for vaginal and rectal use: possibility of rectal use in pediatric practice
- the ability to control the medicinal properties and therapeutic effect of the drug when used in women of reproductive age: with rectal administration of the drug, high bioavailability (more than 80%) of interferon is achieved, and therefore provides a pronounced systemic immunomodulatory effect2;
- when used intravaginally , due to the high concentration at the site of infection and fixation on the cells of the mucous membrane, a pronounced local antiviral, antiproliferative and antibacterial effect is achieved2.
Indications for the use of suppositories GENFERON® LITE 250 thousand IU:
- as a component of complex therapy – for the treatment of acute respiratory viral infections and other acute infectious diseases of bacterial and viral etiology in adults and children over 7 years of age;
- in complex therapy of chronic infectious and inflammatory diseases of viral etiology in children over 7 years of age;
- for the treatment of infectious and inflammatory diseases of the urogenital tract against the background of specific therapy prescribed and supervised by a physician in: children over 7 years of age;
- pregnant women at a period of 13–40 weeks (II-III trimesters of pregnancy);
- women of all ages.
Genferon Light suppositories 250000IU+5mg No. 10
A country
Russia
The country of production may vary depending on the batch of goods. Please check with the operator for detailed information when confirming your order.
Active substance
Interferon alpha-2b + Taurine
Compound
Interferon alpha-2b, taurine.
pharmachologic effect
Has local and systemic effects. The drug contains recombinant human interferon alpha-2b. Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. The immunomodulatory effect is manifested, first of all, by enhancing cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by reactions of the immune system, enhanced under the influence of interferon. Taurine helps to normalize metabolic processes and tissue regeneration, has a membrane-stabilizing and immunomodulatory effect. Taurine helps maintain the biological activity of interferon, enhancing the therapeutic effect of the drug. With rectal administration of the drug, high bioavailability of interferon is observed, and therefore both local and pronounced systemic immunomodulatory effects are achieved; when used intravaginally, due to the high concentration at the site of infection and fixation on the cells of the mucous membrane, a pronounced local antiviral, antiproliferative and antibacterial effect is achieved, while the systemic effect is insignificant due to the low absorption capacity of the vaginal mucosa. The maximum concentration of interferon in the blood serum is achieved 5 hours after administration of the drug. The main route of elimination of α-interferon is renal catabolism. The half-life is 12 hours, which necessitates the use of the drug 2 times a day.
Indications for use
For the treatment of infectious and inflammatory diseases of the urogenital tract in children and women, including pregnant women. As a component of complex therapy - for the treatment of other infectious diseases of viral etiology.
Interaction
The drug is most effective as a component of complex therapy. When combined with antibacterial, fungicidal and antiviral drugs, mutual potentiation of action is observed, which makes it possible to achieve a high total therapeutic effect
Side effect
Local allergic reactions (itching and burning sensation in the vagina). These phenomena are reversible and disappear within 72 hours after cessation of administration. Continuation of treatment is possible after consultation with a doctor. Phenomena that occur when using all types of interferon alfa-2b may be observed, such as chills, fever, fatigue, loss of appetite, muscle and headaches, joint pain, sweating, as well as leukemia and thrombocytopenia. In these cases, it is recommended to consult your doctor to decide whether to discontinue the drug or reduce the dose.
Contraindications
Individual intolerance to interferon and other substances included in the drug. With caution: Exacerbation of allergic and autoimmune diseases. Use during pregnancy and lactation: Clinical studies have proven the effectiveness and safety of the drug in the second and third trimesters of pregnancy. The safety of using the drug in the first trimester of pregnancy has not been studied.
Overdose
If you accidentally administer more suppositories at a time than were prescribed by your doctor, further administration should be suspended for 24 hours, after which treatment can be resumed according to the prescribed regimen.
special instructions
The drug does not affect the performance of potentially hazardous activities that require special attention and quick reactions (driving vehicles, machinery, etc.).
Dispensing conditions in pharmacies
On prescription
Genferon light Suppositories, 10 pcs, 250000 IU, vaginal
Directions for use and doses
The drug can be used both vaginally and rectally.
The route of administration, dose and course duration depend on age and the specific clinical situation. In adults and children over 7 years of age, Genferon Light is used in a dose of 250,000 IU of interferon alfa-2b per suppository. In children under 7 years of age, including infants, it is safe to use the drug at a dose of 125,000 IU of interferon alfa-2b per suppository. In women who are 13-40 weeks pregnant, the drug is used at a dose of 250,000 IU of interferon alfa-2b per suppository. Recommended doses and treatment regimens:
● Acute respiratory viral infections and other acute diseases of a viral nature in children: 1 suppository rectally 2 times a day with a 12-hour interval parallel to the main therapy for 5 days. If, after a 5-day treatment period, the symptoms of the disease do not decrease or become more pronounced, the patient should consult a doctor. According to clinical indications, it is possible to repeat the course of treatment after a 5-day interval.
● Acute respiratory viral infections in frequently and long-term ill children aged 3 to 6 years: 1 suppository (125,000 IU) rectally 2 times a day with an interval of 12 hours for 10 days parallel to standard therapy. After completing the main period of treatment for an acute respiratory viral infection, it is possible to switch to a prophylactic regimen: 1 suppository (125,000 IU) rectally 1 time at night, every other day for 3 weeks.
● Chronic infectious and inflammatory diseases of viral etiology in children over 7 years of age: 1 suppository (250,000 IU) rectally 2 times a day with a 12-hour interval parallel to standard therapy for 10 days. Then for 1-3 months - 1 suppository rectally at night every other day.
● Acute infectious and inflammatory diseases of the urogenital tract in children: 1 suppository rectally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.
● Infectious and inflammatory diseases of the urogenital tract in pregnant women: 1 suppository (250,000 IU) vaginally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.
● Infectious and inflammatory diseases of the urogenital tract in women: 1 suppository (250,000 IU) vaginally or rectally (depending on the nature of the disease) 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor. For prolonged forms, 1 suppository 3 times a week, every other day, for 1-3 months.
Genferon suppositories No. 10 55 mg+1 million IU+10 mg
GENFERON is a combination drug, the effect of which is determined by the components included in its composition. Has local and systemic effects.
The drug Genferon includes recombinant human interferon alpha-2b, produced by a strain of the bacterium Escherichia coli, into which the human interferon alpha-2b gene has been introduced using genetic engineering methods.
Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. The antiviral effect is mediated by the activation of a number of intracellular enzymes that inhibit viral replication. The immunomodulatory effect is manifested, first of all, by enhancing cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. This is achieved through the activation of CD8+ T killer cells, NK cells (natural killer cells), increased differentiation of B lymphocytes and their production of antibodies, activation of the monocyte-macrophage system and phagocytosis, as well as increased expression of molecules of the major histocompatibility complex type I, which increases the likelihood recognition of infected cells by cells of the immune system. Activation of leukocytes contained in all layers of the mucous membrane under the influence of interferon ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, the production of secretory immunoglobulin A is restored. The antibacterial effect is mediated by reactions of the immune system, enhanced under the influence of interferon.
Taurine helps normalize metabolic processes and tissue regeneration, has membrane-stabilizing and immunomodulatory effects. Being a strong antioxidant, taurine directly interacts with reactive oxygen species, the excessive accumulation of which contributes to the development of pathological processes. Taurine helps maintain the biological activity of interferon, enhancing the therapeutic effect of the drug.
Benzocaine (anesthetic) is a local anesthetic. Reduces the permeability of the cell membrane to sodium ions, displaces calcium ions from receptors located on the inner surface of the membrane, and blocks the conduction of nerve impulses. Prevents the occurrence of pain impulses at the endings of sensory nerves and their conduction along nerve fibers. It has an exclusively local effect, without being absorbed into the systemic circulation.
GENFERON LIGHT 250000IU+5MG N10 SUPP VAGINAL/RECTAL
The drug can be used both vaginally and rectally. The route of administration, dose and course duration depend on age and the specific clinical situation. In adults and children over 7 years of age, Genferon® Light is used at a dose of 250,000 IU of interferon alfa-2b per suppository. In children under 7 years of age, including infants, it is safe to use the drug at a dose of 125,000 IU of interferon alfa-2b per suppository. In women who are 13–40 weeks pregnant, the drug is used at a dose of 250,000 IU of interferon alfa-2b per suppository.
Recommended doses and treatment regimens:
– Acute respiratory viral infections and other acute diseases of a viral nature in children:
1 suppository rectally 2 times a day with a 12-hour interval parallel to the main therapy for 5 days. If, after a 5-day treatment period, the symptoms of the disease do not decrease or become more pronounced, the patient should consult a doctor. According to clinical indications, it is possible to repeat the course of treatment after a 5-day interval.
– Acute respiratory viral infections in frequently and long-term ill children aged 3 to 6 years:
1 suppository (125,000 IU) rectally 2 times a day with an interval of 12 hours for 10 days parallel to standard therapy. After completing the main period of treatment for an acute respiratory viral infection, it is possible to switch to a prophylactic regimen: 1 suppository (125,000 IU) rectally 1 time at night, every other day for 3 weeks.
– Chronic infectious and inflammatory diseases of viral etiology in children over 7 years of age:
1 suppository (250,000 IU) rectally 2 times a day with a 12-hour interval parallel to standard therapy for 10 days. Then for 1-3 months - 1 suppository rectally at night every other day.
– Acute infectious and inflammatory diseases of the urogenital tract in children:
1 suppository rectally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.
– Infectious and inflammatory diseases of the urogenital tract in pregnant women:
1 suppository (250,000 IU) vaginally 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor.
– Infectious and inflammatory diseases of the urogenital tract in women:
1 suppository (250,000 IU) vaginally or rectally (depending on the nature of the disease) 2 times a day with a 12-hour interval for 10 days against the background of specific therapy prescribed and supervised by a doctor. For prolonged forms, 1 suppository 3 times a week, every other day, for 1–3 months.
